贝伐-话题@MedSci

#贝伐#

228篇内容 | 3553人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1476952, encodeId=3ca714e6952d3, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), objectType=article, longId=41274, objectId=a319412e4e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a319412e4e0, replyNumber=0, likeNumber=55, createdTime=2014-10-16, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a319412e4e0, moduleTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a319412e4e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476951, encodeId=b40414e69511e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ESMO 2014：抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好, objectType=article, longId=40875, objectId=3d03408e567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d03408e567, replyNumber=0, likeNumber=63, createdTime=2014-10-04, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d03408e567, moduleTitle=ESMO 2014：抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d03408e567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476950, encodeId=e81914e695054, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=APJCP：中国转移性结直肠癌患者中贝伐单抗治疗时间决定疗效, objectType=article, longId=39877, objectId=6772398e791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6772398e791, replyNumber=0, likeNumber=56, createdTime=2014-09-04, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6772398e791, moduleTitle=APJCP：中国转移性结直肠癌患者中贝伐单抗治疗时间决定疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6772398e791)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476949, encodeId=54ff14e694935, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=罗氏贝伐单抗新适应症获美国FDA快速审批, objectType=article, longId=37979, objectId=37d13e979bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d13e979bc, replyNumber=0, likeNumber=93, createdTime=2014-07-20, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d13e979bc, moduleTitle=罗氏贝伐单抗新适应症获美国FDA快速审批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37d13e979bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476947, encodeId=f97014e6947d9, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), objectType=article, longId=37048, objectId=c4a63e048dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4a63e048dd, replyNumber=0, likeNumber=89, createdTime=2014-06-27, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4a63e048dd, moduleTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4a63e048dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476948, encodeId=720d14e6948ce, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Anticancer Res：S-1、伊立替康联合贝伐单抗治疗转移性结直肠癌患者的II期试验, objectType=article, longId=37050, objectId=bd5b3e0501d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd5b3e0501d, replyNumber=0, likeNumber=66, createdTime=2014-06-27, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd5b3e0501d, moduleTitle=Anticancer Res：S-1、伊立替康联合贝伐单抗治疗转移性结直肠癌患者的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd5b3e0501d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476946, encodeId=67de14e694614, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Cancer Chemother Pharmacol：贝伐单抗应用延长与NF2患者长期毒性相关, objectType=article, longId=36454, objectId=9394364549b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9394364549b, replyNumber=0, likeNumber=54, createdTime=2014-06-18, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9394364549b, moduleTitle=Cancer Chemother Pharmacol：贝伐单抗应用延长与NF2患者长期毒性相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9394364549b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476945, encodeId=e04114e69450b, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, objectType=article, longId=36094, objectId=bf553609449, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf553609449, replyNumber=0, likeNumber=77, createdTime=2014-06-08, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf553609449, moduleTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf553609449)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476944, encodeId=700e14e6944c0, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2014：贝伐单抗+化疗方案和西妥昔单抗+化疗方案一线治疗转移性结直肠癌患者的疗效的研究（CALGB/SWOG 80405研究）, objectType=article, longId=35755, objectId=885735e5522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=885735e5522, replyNumber=0, likeNumber=54, createdTime=2014-06-04, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=885735e5522, moduleTitle=ASCO 2014：贝伐单抗+化疗方案和西妥昔单抗+化疗方案一线治疗转移性结直肠癌患者的疗效的研究（CALGB/SWOG 80405研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=885735e5522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476943, encodeId=761d14e6943e7, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2014：贝伐单抗加化疗用于直肠癌术前治疗的II期临床试验, objectType=article, longId=35259, objectId=6fa835259a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fa835259a8, replyNumber=0, likeNumber=47, createdTime=2014-05-25, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fa835259a8, moduleTitle=ASCO 2014：贝伐单抗加化疗用于直肠癌术前治疗的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fa835259a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476942, encodeId=f6e914e694276, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2014：贝伐单抗标准化疗用于SCLC疗效欠佳, objectType=article, longId=35084, objectId=0a903508402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a903508402, replyNumber=0, likeNumber=78, createdTime=2014-05-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a903508402, moduleTitle=ASCO 2014：贝伐单抗标准化疗用于SCLC疗效欠佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a903508402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476941, encodeId=01e814e6941d8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, objectType=article, longId=35032, objectId=208c35032c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208c35032c3, replyNumber=0, likeNumber=77, createdTime=2014-05-22, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208c35032c3, moduleTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208c35032c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476940, encodeId=ea7514e6940cd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=NEJM：贝伐单抗一线治疗不改善新诊胶质母细胞瘤生存, objectType=article, longId=31603, objectId=0dec316038d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0dec316038d, replyNumber=0, likeNumber=62, createdTime=2014-03-08, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0dec316038d, moduleTitle=NEJM：贝伐单抗一线治疗不改善新诊胶质母细胞瘤生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dec316038d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476939, encodeId=a9b114e69395e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=GCS 2014：序贯卡培他滨加贝伐单抗维持治疗对转移性结直肠癌有获益（CAIRO3试验）, objectType=article, longId=31289, objectId=c813312897c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c813312897c, replyNumber=0, likeNumber=64, createdTime=2014-03-01, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c813312897c, moduleTitle=GCS 2014：序贯卡培他滨加贝伐单抗维持治疗对转移性结直肠癌有获益（CAIRO3试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c813312897c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476938, encodeId=d1ed14e693857, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐单抗一线应用可使中国肺癌患者显著获益（BEYOND研究）, objectType=article, longId=27001, objectId=73372e0018c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73372e0018c, replyNumber=0, likeNumber=58, createdTime=2013-11-25, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73372e0018c, moduleTitle=贝伐单抗一线应用可使中国肺癌患者显著获益（BEYOND研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73372e0018c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476937, encodeId=854a14e6937d0, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=JCO：不建议厄洛替尼联合贝伐单抗用于晚期NSCLC维持治疗, objectType=article, longId=25618, objectId=38b32561839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38b32561839, replyNumber=0, likeNumber=88, createdTime=2013-10-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38b32561839, moduleTitle=JCO：不建议厄洛替尼联合贝伐单抗用于晚期NSCLC维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38b32561839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476936, encodeId=37a514e6936c2, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Ann Oncol：短期放疗再加贝伐和化疗对原发转移性直肠癌具有良好疗效, objectType=article, longId=22129, objectId=81ce2212933, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81ce2212933, replyNumber=0, likeNumber=57, createdTime=2013-07-28, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81ce2212933, moduleTitle=Ann Oncol：短期放疗再加贝伐和化疗对原发转移性直肠癌具有良好疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81ce2212933)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476935, encodeId=087814e69352e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2013：贝伐珠单抗一线治疗无益于胶质瘤患者生存, objectType=article, longId=20248, objectId=30be20248b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30be20248b2, replyNumber=0, likeNumber=102, createdTime=2013-06-20, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30be20248b2, moduleTitle=ASCO 2013：贝伐珠单抗一线治疗无益于胶质瘤患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30be20248b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476934, encodeId=3d9114e693420, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2013：贝伐单抗联合伊立替康治疗胶质母细胞瘤优于替莫唑胺, objectType=article, longId=19953, objectId=b357199535c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b357199535c, replyNumber=0, likeNumber=68, createdTime=2013-06-10, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b357199535c, moduleTitle=ASCO 2013：贝伐单抗联合伊立替康治疗胶质母细胞瘤优于替莫唑胺, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b357199535c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476933, encodeId=7df614e693398, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO 2013：头对头研究显示晚期结肠癌一线治疗西妥昔单抗优于贝伐单抗, objectType=article, longId=19577, objectId=bf9e195e744, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9e195e744, replyNumber=0, likeNumber=54, createdTime=2013-06-04, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9e195e744, moduleTitle=ASCO 2013：头对头研究显示晚期结肠癌一线治疗西妥昔单抗优于贝伐单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf9e195e744)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐

2020-05-29

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究)

2014-10-16

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ESMO 2014：抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好

2014-10-04

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

APJCP：中国转移性结直肠癌患者中贝伐单抗治疗时间决定疗效

2014-09-04

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

罗氏贝伐单抗新适应症获美国FDA快速审批

2014-07-20

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究)

2014-06-27

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Anticancer Res：S-1、伊立替康联合贝伐单抗治疗转移性结直肠癌患者的II期试验

2014-06-27

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Cancer Chemother Pharmacol：贝伐单抗应用延长与NF2患者长期毒性相关

2014-06-18

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益

2014-06-08

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2014：贝伐单抗+化疗方案和西妥昔单抗+化疗方案一线治疗转移性结直肠癌患者的疗效的研究（CALGB/SWOG 80405研究）

2014-06-04

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2014：贝伐单抗加化疗用于直肠癌术前治疗的II期临床试验

2014-05-25

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2014：贝伐单抗标准化疗用于SCLC疗效欠佳

2014-05-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）

2014-05-22

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

NEJM：贝伐单抗一线治疗不改善新诊胶质母细胞瘤生存

2014-03-08

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

GCS 2014：序贯卡培他滨加贝伐单抗维持治疗对转移性结直肠癌有获益（CAIRO3试验）

2014-03-01

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐单抗一线应用可使中国肺癌患者显著获益（BEYOND研究）

2013-11-25

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

JCO：不建议厄洛替尼联合贝伐单抗用于晚期NSCLC维持治疗

2013-10-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Ann Oncol：短期放疗再加贝伐和化疗对原发转移性直肠癌具有良好疗效

2013-07-28

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2013：贝伐珠单抗一线治疗无益于胶质瘤患者生存

2013-06-20

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2013：贝伐单抗联合伊立替康治疗胶质母细胞瘤优于替莫唑胺

2013-06-10

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO 2013：头对头研究显示晚期结肠癌一线治疗西妥昔单抗优于贝伐单抗

2013-06-04

科室
- - 订阅+
  - 更多科室
工具
服务